{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:35:49Z","timestamp":1767141349240,"version":"build-2238731810"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:00:00Z","timestamp":1550534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10157-019-01715-8","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:25:58Z","timestamp":1550535958000},"page":"841-851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Regional prescription surveillance of phosphate binders in the western Saitama area: the substantial role of ferric citrate hydrate in improving serum phosphorus levels and erythropoiesis"],"prefix":"10.1007","volume":"23","author":[{"given":"Hiroaki","family":"Amano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Tomori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Ohama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,19]]},"reference":[{"issue":"3","key":"1715_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1542-4758.2007.00190.x","volume":"11","author":"N Kimata","year":"2007","unstructured":"Kimata N, Albert JM, Akiba T, Yamazaki S, Kawaguchi T, Fukuhara S, et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan dialysis outcomes and practice patterns study. Hemodial Int. 2007;11(3):340\u20138. \n                    https:\/\/doi.org\/10.1111\/j.1542-4758.2007.00190.x\n                    \n                  .","journal-title":"Hemodial Int"},{"issue":"5","key":"1715_CR2","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2215\/cjn.01060308","volume":"3","author":"MD Danese","year":"2008","unstructured":"Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(5):1423\u20139. \n                    https:\/\/doi.org\/10.2215\/cjn.01060308\n                    \n                  .","journal-title":"Clin J Am Soc Nephrol"},{"key":"1715_CR3","doi-asserted-by":"publisher","DOI":"10.7326\/m17-2640","author":"M Ketteler","year":"2018","unstructured":"Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the kidney disease: improving global outcomes 2017 clinical practice guideline update. Ann Intern Med. 2018. \n                    https:\/\/doi.org\/10.7326\/m17-2640\n                    \n                  .","journal-title":"Ann Intern Med"},{"issue":"3","key":"1715_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1744-9987.12058","volume":"17","author":"M Fukagawa","year":"2013","unstructured":"Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17(3):247\u201388. \n                    https:\/\/doi.org\/10.1111\/1744-9987.12058\n                    \n                  .","journal-title":"Ther Apher Dial"},{"issue":"6","key":"1715_CR5","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2215\/cjn.00290109","volume":"4","author":"YW Chiu","year":"2009","unstructured":"Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089\u201396. \n                    https:\/\/doi.org\/10.2215\/cjn.00290109\n                    \n                  .","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"1715_CR6","first-page":"287","volume":"110","author":"J Hammer","year":"1998","unstructured":"Hammer J, Oesterreicher C, Hammer K, Koch U, Traindl O, Kovarik J. Chronic gastrointestinal symptoms in hemodialysis patients. Wien Klin Wochenschr. 1998;110(8):287\u201391.","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"1715_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1053\/j.ackd.2006.10.001","volume":"14","author":"FE Murtagh","year":"2007","unstructured":"Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007;14(1):82\u201399. \n                    https:\/\/doi.org\/10.1053\/j.ackd.2006.10.001\n                    \n                  .","journal-title":"Adv Chronic Kidney Dis"},{"key":"1715_CR8","doi-asserted-by":"publisher","first-page":"9792363","DOI":"10.1155\/2017\/9792363","volume":"2017","author":"Z Gebretsadik","year":"2017","unstructured":"Gebretsadik Z, Gebrehans M, Getnet D, Gebrie D, Alema T, Belay YB. Assessment of drug-drug interaction in ayder comprehensive specialized Hospital, Mekelle, Northern Ethiopia: a retrospective study. Biomed Res Int. 2017;2017:9792363. \n                    https:\/\/doi.org\/10.1155\/2017\/9792363\n                    \n                  .","journal-title":"Biomed Res Int"},{"issue":"3","key":"1715_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ekir.2016.12.005","volume":"2","author":"K Yokoyama","year":"2017","unstructured":"Yokoyama K, Fukagawa M, Akiba T, Nakayama M, Otoguro T, Yamada K, et al. Ferritin elevation and improved responsiveness to erythropoiesis-stimulating agents in patients on ferric citrate hydrate. Kidney Int Rep. 2017;2(3):359\u201365. \n                    https:\/\/doi.org\/10.1016\/j.ekir.2016.12.005\n                    \n                  .","journal-title":"Kidney Int Rep"},{"issue":"10","key":"1715_CR10","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1681\/ASN.2014080842","volume":"26","author":"K Umanath","year":"2015","unstructured":"Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, et al. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol. 2015;26(10):2578\u201387. \n                    https:\/\/doi.org\/10.1681\/ASN.2014080842\n                    \n                  .","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1715_CR11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1053\/j.ajkd.2016.05.015","volume":"68","author":"SC Palmer","year":"2016","unstructured":"Palmer SC, Gardner S, Tonelli M, Mavridis D, Johnson DW, Craig JC, et al. Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials. Am J Kidney Dis. 2016;68(5):691\u2013702. \n                    https:\/\/doi.org\/10.1053\/j.ajkd.2016.05.015\n                    \n                  .","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1715_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1681\/asn.2014020212","volume":"26","author":"JB Lewis","year":"2015","unstructured":"Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015;26(2):493\u2013503. \n                    https:\/\/doi.org\/10.1681\/asn.2014020212\n                    \n                  .","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"1715_CR13","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1093\/ndt\/gfq802","volume":"26","author":"V Panichi","year":"2011","unstructured":"Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant. 2011;26(8):2641\u20138. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfq802\n                    \n                  .","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1715_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. \n                    https:\/\/doi.org\/10.1038\/bmt.2012.244\n                    \n                  .","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1715_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1523-1755.1999.00240.x","volume":"55","author":"EA Slatopolsky","year":"1999","unstructured":"Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 1999;55(1):299\u2013307. \n                    https:\/\/doi.org\/10.1046\/j.1523-1755.1999.00240.x\n                    \n                  .","journal-title":"Kidney Int"},{"key":"1715_CR16","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1046\/j.1523-1755.63.s85.18.x","volume":"63","author":"Patrick C. D'Haese","year":"2003","unstructured":"D\u2019Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl. 2003(85):S73-8. \n                    https:\/\/doi.org\/10.1046\/j.1523-1755.63.s85.18.x\n                    \n                  .","journal-title":"Kidney International"},{"issue":"3","key":"1715_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/nejm198607173150304","volume":"315","author":"E Slatopolsky","year":"1986","unstructured":"Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med. 1986;315(3):157\u201361. \n                    https:\/\/doi.org\/10.1056\/nejm198607173150304\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"2","key":"1715_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/1744-9987.12068","volume":"18","author":"T Akizawa","year":"2014","unstructured":"Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kawasaki S, Bixalomer Study G. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Ther Apher Dial. 2014;18(2):122\u201331. \n                    https:\/\/doi.org\/10.1111\/1744-9987.12068\n                    \n                  .","journal-title":"Ther Apher Dial"},{"issue":"1","key":"1715_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/hdi.12315","volume":"20","author":"RB Fissell","year":"2016","unstructured":"Fissell RB, Karaboyas A, Bieber BA, Sen A, Li Y, Lopes AA, et al. Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS. Hemodial Int. 2016;20(1):38\u201349. \n                    https:\/\/doi.org\/10.1111\/hdi.12315\n                    \n                  .","journal-title":"Hemodial Int"},{"issue":"11","key":"1715_CR20","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1093\/ndt\/gft280","volume":"29","author":"S Wang","year":"2014","unstructured":"Wang S, Alfieri T, Ramakrishnan K, Braunhofer P, Newsome BA. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant. 2014;29(11):2092\u20139. \n                    https:\/\/doi.org\/10.1093\/ndt\/gft280\n                    \n                  .","journal-title":"Nephrol Dial Transplant"},{"key":"1715_CR21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/1471-2369-14-208","volume":"14","author":"MT Martins","year":"2013","unstructured":"Martins MT, Silva LF, Kraychete A, Reis D, Dias L, Schnitman G, et al. Potentially modifiable factors associated with non-adherence to phosphate binder use in patients on hemodialysis. BMC Nephrol. 2013;14:208. \n                    https:\/\/doi.org\/10.1186\/1471-2369-14-208\n                    \n                  .","journal-title":"BMC Nephrol"},{"issue":"20","key":"1715_CR22","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/nejm200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478\u201383. \n                    https:\/\/doi.org\/10.1056\/nejm200005183422003\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"9","key":"1715_CR23","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2215\/cjn.13091216","volume":"12","author":"H Komaba","year":"2017","unstructured":"Komaba H, Wang M, Taniguchi M, Yamamoto S, Nomura T, Schaubel DE, et al. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders. Clin J Am Soc Nephrol. 2017;12(9):1489\u201397. \n                    https:\/\/doi.org\/10.2215\/cjn.13091216\n                    \n                  .","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1715_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","volume":"62","author":"GM Chertow","year":"2002","unstructured":"Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245\u201352. \n                    https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00434.x\n                    \n                  .","journal-title":"Kidney Int"},{"issue":"2","key":"1715_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/1744-9987.12399","volume":"20","author":"K Tsuchida","year":"2016","unstructured":"Tsuchida K, Nagai K, Yokota N, Minakuchi J, Kawashima S. Impact of lanthanum carbonate on prognosis of chronic hemodialysis patients: a retrospective cohort study (Kawashima Study). Ther Apher Dial. 2016;20(2):142\u20138. \n                    https:\/\/doi.org\/10.1111\/1744-9987.12399\n                    \n                  .","journal-title":"Ther Apher Dial"},{"issue":"2","key":"1715_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1744-9987.2010.00898.x","volume":"15","author":"T Shigematsu","year":"2011","unstructured":"Shigematsu T, Tokumoto A, Nakaoka A, Arisaka H. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. Ther Apher Dial. 2011;15(2):176\u201384. \n                    https:\/\/doi.org\/10.1111\/j.1744-9987.2010.00898.x\n                    \n                  .","journal-title":"Ther Apher Dial"}],"updated-by":[{"DOI":"10.1007\/s10157-019-01790-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000}}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-019-01715-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01715-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01715-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T19:24:11Z","timestamp":1582053851000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-019-01715-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,19]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1715"],"URL":"https:\/\/doi.org\/10.1007\/s10157-019-01715-8","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,19]]},"assertion":[{"value":"4 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the Original publication, Under the table\u00a01, the number of participants in the April has been incorrectly published as 1373. The corrected table is given below.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The contributing authors reported the following financial supports: Hirokazu Okada received Astellas Pharma Inc, Takeda Pharmacological Company, Pfizer Japan Inc, MSD Inc, Novartis Pharma Japan, Otsuka Pharmacological Inc, Kyowa Hakko Kirin, Daiichi Sankyo Inc, Mitsubishi Tanabe Parma, Cyugai Pharma, Torii Pharma, Bayer Yakuhin, Boehringer-Ingelheim Japan, and Eli Lilly Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee at which the studies were conducted (IRB approval number 16\u2013023) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"We obtained consent through the opt-out procedure from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}